Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.60 |
| ▸ | F2 | P00734 | 6/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730519 | 0.97 | F10 (0.60) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL16730426 | 0.94 | F10 (0.64) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL18028151 | 0.91 | F10 (0.65) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL16730534 | 0.91 | F10 (0.72) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL16730536 | 0.89 | F10 (0.49) | F10F2SLC29A1CCNA2CDK2 | |
| SCHEMBL16730295 | 0.89 | F10 (0.76) | F10F2SLC29A1 | |
| SCHEMBL16730537 | 0.89 | F10 (0.47) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL16730301 | 0.89 | F10 (0.46) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL541837 | 0.88 | F10 (0.77) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL16730287 | 0.88 | PDE4A (0.52) | F10F2SLC29A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| EP-3072892-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2015070809-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 成都苑东药业有限公司 | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | F10 35/4885F2 2/4885SLC29A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.